» Articles » PMID: 35659945

Frailty Prevalence and Impact on Outcomes in Patients with Atrial Fibrillation: A Systematic Review and Meta-analysis of 1,187,000 Patients

Overview
Journal Ageing Res Rev
Specialty Geriatrics
Date 2022 Jun 6
PMID 35659945
Authors
Affiliations
Soon will be listed here.
Abstract

Frailty is a clinical syndrome characterized by a reduced physiologic reserve, increased vulnerability to stressors and an increased risk of adverse outcomes. People with atrial fibrillation (AF) are often burdened by frailty due to biological, clinical, and social factors. The prevalence of frailty, its management and association with major outcomes in AF patients are still not well quantified. We systematically searched PubMed and EMBASE, from inception to September 13th, 2021, for studies reporting the prevalence of frailty in AF patients. The study was registered in PROSPERO (CRD42021235854). 33 studies were included in the systematic review (n = 1,187,651 patients). The frailty pooled prevalence was 39.7 % (95 %CI=29.9 %-50.5 %, I =100 %), while meta-regression analyses showed it is influenced by age, history of stroke, and geographical location. Meta-regression analyses showed that OAC prescription was influenced by study-level mean age, baseline thromboembolic risk, and study setting. Frail AF patients were associated with a higher risk of all-cause death (OR=5.56, 95 %CI=3.46-8.94), ischemic stroke (OR=1.59, 95 %CI=1.00-2.52), and bleeding (OR=1.64, 95 %CI=1.11-2.41), when compared to robust individuals. In this systematic review and meta-analysis, the prevalence of frailty was high in patients with AF. Frailty may influence the prognosis and management of AF patients, thus requiring person-tailored interventions in a holistic or integrated approach to AF care.

Citing Articles

Outcomes in Atrial Fibrillation Patients with Different Clinical Phenotypes: Insights from the French Population.

Fawzy A, Bisson A, Lochon L, Lenormand T, Lip G, Fauchier L J Clin Med. 2025; 14(4).

PMID: 40004575 PMC: 11856015. DOI: 10.3390/jcm14041044.


Atrial Fibrillation as a Geriatric Syndrome: Why Are Frailty and Disability Often Confused? A Geriatric Perspective from the New Guidelines.

Testa C, Salvi M, Zucchini I, Cattabiani C, Giallauria F, Petraglia L Int J Environ Res Public Health. 2025; 22(2).

PMID: 40003404 PMC: 11855129. DOI: 10.3390/ijerph22020179.


Risk factors of stroke-related sarcopenia: a systematic review and meta-analysis.

Yan H, Li J, Xian L, Li Y, Li S, Wen Q Front Aging. 2025; 6:1452708.

PMID: 39967995 PMC: 11833335. DOI: 10.3389/fragi.2025.1452708.


Incidence and Predictors of Clinical Outcomes in Real-Life Patients With Atrial Fibrillation Treated With Oral Factor Xa Inhibitors: The Follow-Up Results of the ANATOLIA-AF Study.

Kocabas U, Ergin I, Sonmez S, Yavuz V, Murat S, Ozdemir I Clin Cardiol. 2025; 48(1):e70088.

PMID: 39871620 PMC: 11773160. DOI: 10.1002/clc.70088.


Direct-Acting Oral Anticoagulants in the Management of Cerebral Venous Sinus Thrombosis-Where Do We Stand?.

Vojjala N, Peshin S, Kattamuri L, Iqbal R, Dharia A, Jayakumar J Biomedicines. 2025; 13(1).

PMID: 39857772 PMC: 11759824. DOI: 10.3390/biomedicines13010189.